Global /United States /Healthcare /Biotechnology /MRNA
chevron_leftBack

Moderna, Inc.

MRNA
NASDAQ: MRNA Delayed
26.54USD 3.1%
As of 24 April 2025, Moderna, Inc. has a market cap of $10.26B USD, ranking #1655 globally and #602 in the United States. It ranks #145 in the Healthcare sector, and #22 in the Biotechnology industry.
Global Rank
1655
Country Rank
602
Sector Rank
145
Industry Rank
22
Key Stats
Market Cap
$10.26BUSD
Enterprise Value
$1.53BUSD
Revenue (TTM)
$3.24BUSD
EBITDA (TTM)
-$3.76BUSD
Net Income (TTM)
-$3.56BUSD
EBITDA Margin
-116%
Profit Margin
-110%
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Stephane Bancel open_in_new
Founded
2010
IPO
07 Dec 2018
Website
modernatx.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
3.1% 5.4% -19% -31% -50% -75%
Upcoming Earnings
Earnings Date
Thu, May 1
Earnings Time
sunny Before Open
EPS Estimate
-$2.93
Revenue Estimate
$194.33M 16% yoy

Markets

Exchange Ticker Price
NASDAQ
MIC: XNAS
PRIMARY
MRNA
Moderna Inc
ISIN: US60770K1079
Shares Out.:
385.816M1 Shares Float: 341.659M2
TV:
SA:
YF:
GF:
NQ:
BA:
MS:
26.54 USD
London Stock Exchange
MIC: XLON
0A45
Moderna Inc
ISIN: US60770K1079
TV:
SA:
YF:
GF:
BA:
MS:
26.89 USD
Frankfurt Stock Exchange
MIC: XFRA
0QF
Moderna Inc
ISIN: US60770K1079
TV:
SA:
YF:
GF:
BA:
0QF
MS:
23.75 EUR
Deutsche Börse Xetra
MIC: XETR
0QF
Moderna Inc
ISIN: US60770K1079
TV:
SA:
YF:
GF:
BA:
0QF
MS:
21.84 EUR
Borsa Italiana
MIC: XMIL
1MRNA
Moderna Inc
ISIN: US60770K1079
TV:
SA:
YF:
GF:
BA:
MS:
22.25 EUR
Mexican Bolsa
MIC: XMEX
MRNA
Moderna Inc
ISIN: US60770K1079
TV:
SA:
YF:
GF:
BA:
MS:
500.00 MXN
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Moderna, Inc.

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as individualized neoantigen and checkpoint adaptive immune modulation therapy; and rare disease products, including propionic and methylmalonic acidemia, glycogen storage disease type 1a, ornithine transcarbamylase deficiency, phenylketonuria, crigler-najjar syndrome type 1, and cystic fibrosis. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Generation Bio Co.; immatics N.V.; Life Edit Therapeutics; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Similar Companies

Industry: Biotechnology (United States)
Name
Market Cap diff.
Vertex Pharmaceuticals Inc.
VRTX
$126.59B
1K%
Regeneron Pharmaceuticals, Inc.
REGN
$62.91B
513%
Alnylam Pharmaceuticals, Inc.
ALNY
$31.35B
206%
Summit Therapeutics Inc.
SMMT
$24.51B
139%
Royalty Pharma plc
RPRX
$18.27B
78%
Industry: Biotechnology (Global)
Name
Market Cap diff.
CSL Ltd.
CSL
$73.89B
116.09B AUD
620%
Samsung Biologics Co.,Ltd.
207940
$53.15B
75.87T KRW
418%
argenx SE
ARGX
$36.51B
32.22B EUR
256%
UCB S.A.
UCB
$30.19B
26.64B EUR
194%
BioNTech SE
BNTX
$27.56B
169%